Press release
Neurofibromatosis Type 1 Market Outlook Highlights Strategic Opportunities Across The Industry
Neurofibromatosis Type 1 Market
Forecasted Market Value and Growth Trajectory for Neurofibromatosis Type 1
The NF1 market is projected to expand significantly, reaching a valuation of $13.78 billion by 2030. This growth will occur at a compound annual growth rate (CAGR) of 9.2%. Several factors are driving this upward trend, including heightened demand for targeted NF1 therapies and increasing investments in precision oncology. Additionally, the market benefits from broader treatment options for optic gliomas, greater access to advanced imaging technologies, and the development of innovative gene-based therapies. Key trends shaping this market include a surge in targeted treatments aimed at tumor reduction, heightened interest in early genetic testing for NF1, expanded surgical options for tumor excision, rising use of radiation therapy specifically for optic gliomas, and a stronger focus on supportive care and counseling services.
The neurofibromatosis type 1 market size has grown strongly in recent years. It will grow from $8.83 billion in 2025 to $9.68 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to early identification of nf1 symptoms, development of pain management treatments, increased diagnosis of plexiform neurofibromas, adoption of surgical tumor removal, rising awareness of genetic counseling.
Download a free sample of the neurofibromatosis type 1 market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21230&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR
Leading Corporations Influencing the Neurofibromatosis Type 1 Market
A variety of prominent companies play pivotal roles in the NF1 market's landscape. These include Pfizer Inc, F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Novartis AG, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, BeiGene Ltd, BioMarin Pharmaceutical Inc, Blueprint Medicines Corporation, SpringWorks Therapeutics Inc, Healx Limited, Infixion Bioscience Limited, NFlection Therapeutics Inc, Pasithea Therapeutics Corporation, Mulberry Biotherapeutics Inc, CureAge Therapeutics, Fosun Pharmaceutical Group Co Ltd, AstraZeneca Plc, Genentech Inc, Regeneron Pharmaceuticals Inc, Amgen Inc, AbbVie Inc, GL Pharm Tech Corporation, and ReCode Therapeutics Inc.
An important development happened in July 2025 when Merck KGaA, headquartered in Germany, acquired SpringWorks Therapeutics for $3.4 billion. This strategic move aimed to broaden Merck's portfolio in rare tumors and reinforce its global oncology initiatives. By integrating SpringWorks' FDA-approved treatments for desmoid tumors and NF1-related plexiform neurofibromas, Merck strengthens its position in this niche. SpringWorks Therapeutics is a US-based company specializing in targeted therapies for rare and genetically defined cancers, including FDA-approved options for desmoid tumors and NF1-associated plexiform neurofibromas.
View the full neurofibromatosis type 1 market report:
https://www.thebusinessresearchcompany.com/report/neurofibromatosis-type-1-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR
Innovations and Emerging Trends Transforming the Neurofibromatosis Type 1 Sector
Companies in the NF1 market are increasingly focusing on launching innovative products like kinase inhibitors to enhance targeted therapy and improve patient outcomes. Kinase inhibitors work by blocking enzyme activities that regulate key cellular functions, making them effective in controlling tumor growth. A notable example occurred in May 2023, when AstraZeneca plc, based in the UK, received approval in China for Koselugo (selumetinib). This drug is approved for treating symptomatic, inoperable plexiform neurofibromas in pediatric patients aged three years and older with NF1. The approval in China broadens access to targeted treatments for young NF1 patients, providing a non-surgical option that supports better disease management and quality of life. Koselugo's introduction aligns with the wider movement toward precision medicine, reflecting a shift to more personalized and less invasive therapies.
Comprehensive Overview of Neurofibromatosis Type 1 Market Segments
The NF1 market is categorized by several key segments in this report:
1) Treatment Types: Medication, Surgery, Radiation Therapy, Other Treatments
2) Disease Variants: Plexiform Neurofibromas, Cutaneous Neurofibromas, Optic Gliomas, Other Diseases
3) Distribution Channels: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) End Users: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End Users
Further subsegments include:
- Medication: Targeted Therapy, Pain Management Medications, Anticonvulsants
- Surgery: Tumor Removal Surgery, Nerve Decompression Surgery
- Radiation Therapy: Stereotactic Radiosurgery, External Beam Radiation Therapy
- Other Treatments: Physical Therapy, Genetic Counseling, Psychological Support and Counseling
These classifications provide a detailed framework for understanding the market's scope and the variety of approaches used in treating NF1 patients.
Our latest 2026 market reports provide expanded strategic and visual intelligence with market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, together with updated graphics and tables.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neurofibromatosis Type 1 Market Outlook Highlights Strategic Opportunities Across The Industry here
News-ID: 4611321 • Views: …
More Releases from The Business Research Company
Neuroprosthetics Market Trends Support A 14.6% CAGR Outlook Through The Forecast …
The neuroprosthetics industry is on the verge of significant transformation as technological advances and growing adoption fuel its expansion. This market is becoming increasingly vital in improving the quality of life for individuals with neurological impairments, combining medical innovation with cutting-edge engineering. Let's explore the current market size, key players, emerging trends, and segmentation within this evolving sector.
Projected Market Size and Growth of the Neuroprosthetics Industry
The neuroprosthetics market…
Neuromyelitis Optica Spectrum Disorder Market Report Examines Industry Trends, G …
The neuromyelitis optica spectrum disorder (NMOSD) market is positioned for substantial expansion in the coming years, driven by advances in targeted therapies and diagnostic technologies. As research and innovation accelerate, this specialized healthcare segment is gaining momentum, offering hope for improved patient outcomes and new treatment options. Below is a detailed overview of the market size, key players, emerging trends, and segmentation within the NMOSD industry.
Projected Market Size and Growth…
Neurological Biomarkers Market Report Examines Leading Companies And Growth Oppo …
The neurological biomarkers market is on a trajectory of significant expansion, driven by advancements in personalized medicine and innovative diagnostic technologies. This sector is gaining attention for its potential to transform the way neurological disorders are detected and managed, offering promising opportunities for healthcare providers and patients alike.
Forecasted Growth and Valuation in the Neurological Biomarkers Market
The market for neurological biomarkers is projected to experience rapid growth, reaching an…
Neurofeedback Market Study Explores Industry Growth Toward $2.59 Billion
The neurofeedback market is steadily gaining traction as mental health awareness and personalized treatment options continue to evolve. Driven by technological advancements and growing adoption of digital health solutions, this sector is set to witness significant expansion over the coming years. Here is a detailed breakdown of the market size, key players, emerging trends, and segmentation that define the future landscape of the neurofeedback industry.
Expected Market Growth and Expansion of…
More Releases for NF1
Neurofibromatosis Type 1 (NF1) Market representing a strong CAGR of 10%-13% duri …
Market Overview
The Neurofibromatosis Type 1 (NF1) market is undergoing a major transformation fueled by advancements in precision oncology, genetic diagnostics, and targeted therapies. NF1 is a common autosomal dominant disorder characterized by café-au-lait spots, plexiform neurofibromas, cutaneous neurofibromas, optic pathway gliomas, skeletal abnormalities, and increased tumor predisposition.
The global market for NF1-related therapies and associated tumor management was valued at an estimated USD 340-440 million in 2024. As novel targeted treatments…
The NF1-PN Market in 7MM to Witness Notable Growth, Expanding from USD 380 milli …
The Neurofibromatosis type 1-associated Plexiform Neurofibromas market across the 7MM is expected to surge owing to an increased awareness, advancements in diagnostic techniques, greater accessibility to genetic testing, and the emergence of new transformative treatments such as KOSELUGO (AstraZeneca and Merck), Mirdametinib (SpringWorks Therapeutics), HLX-1502 (Healx), FCN-159 (Fosun Pharmaceutical), and AS-004 (Pasithea Therapeutics).
DelveInsight's report titled "Neurofibromatosis Type 1-associated Plexiform Neurofibromas (NF1-PN): Market Insights, Epidemiology, and Market Forecast - 2034" offers…
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Pois …
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Summary
NF1-PN Market Set to Grow Beyond USD 380 Million by 2034 driven by rising diagnosed cases, better awareness, advanced diagnostics, and genetic testing. In the US alone, ~97,000 diagnosed NF1 cases were reported in 2023, expected to increase by 2034. Treatment remains challenging-surgery is often complex, risky, and prone to recurrence, leaving significant unmet needs, especially in pediatric patients with inoperable PNs. Current…
Neurofibromatosis Type 1 Treatment Landscape: FDA Expands KOSELUGO Approval to Y …
DelveInsight Business Research's analysis underscores the transformative impact of the FDA's September 10, 2025 approval of KOSELUGO (selumetinib) granules and capsules for pediatric patients aged 1 year and older with symptomatic, inoperable plexiform neurofibromas (PN) associated with Neurofibromatosis Type 1 (NF1). This expansion marks the first therapy targeting NF1-PN in this younger age group, offering hope to ~97,000 diagnosed children in the US.
Key NF1 Market Highlights
*
The Neurofibromatosis Type 1 treatment…
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market to R …
Neurofibromatosis type 1 (NF1) is a rare, genetic tumor predisposition disorder caused by mutations in the NF1 gene. Among its manifestations, plexiform neurofibromas (PNs) are one of the most severe complications. These benign but often disfiguring and painful tumors can cause neurological impairment, airway obstruction, spinal deformities, and malignant transformation in rare cases.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71719
Until recently, management relied on surgery, which is often…
Neurofibromatosis Type 1 (NF1) Market to Reach USD 2.5 Billion by 2034
Neurofibromatosis Type 1 (NF1) is one of the most common genetic disorders among rare diseases, affecting approximately 1 in 3,000 individuals worldwide. It is caused by mutations in the NF1 gene, which encodes neurofibromin, a protein that helps regulate cell growth. Patients with NF1 develop benign tumors along nerves, skin abnormalities, and in some cases, malignant peripheral nerve sheath tumors (MPNSTs).
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71663
Historically,…
